This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): sustained release bevacizumab, Tethadur
pSivida is evaluating a sustained release form of Avastin (bevacizumab), using the Company's Tethadur delivery technology.
pSivida’s Tethadur utilizes a tunable nano-porous, elemental silicon-based structure to provide sustained delivery of large biologic molecules.
Sustained-Release Bevacizumab News
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Pink Sheet US FDA, Advisory Committees Rarely Disagree
Additional information available to subscribers only: